CAS: 253801-04-6; 1H-Indazole-5-Carbaldehyde

上下游产品

CAS号53857-57-1 5-溴吲唑 | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号201230-82-2 carbon monoxide | CAS号55919-82-9 5-碘-1H-吲唑 | CAS号141-53-7 甲酸钠 | CAS号88990-57-2 (4-氨基-3-甲基苯基)甲醇 | CAS号944899-01-8 3-碘-1H-吲唑-5-甲醛 | CAS号74626-47-4 吲唑-5-甲腈 | CAS号1086391-08-3 3-溴-1H-吲唑-5-甲醛 | CAS号1086391-03-8 3-氯-1H-吲唑-5-甲醛 | CAS号92160-67-3 1-(4-methylphen... | CAS号635713-15-4 3-(1H-indazol-5... | CAS号635713-71-2 1-N-B°C-5-甲酰基吲唑

📜4-氨基-3-甲基苯甲醇置于18-冠醚-6,Potassium Acetate,戴斯-马丁氧化剂,Sodium Hydroxide,亚硝酸异戊酯体系中,用 甲醇,二氯甲烷,氯仿 用作溶剂,化学反应 30.0H,反应生成1H-吲唑-5-甲醛
参考文献:Discovery Of Potent And Selective Nonsteroidal Indazolyl Amide Glucocorticoid Receptor Agonists
标题:Discovery Of Potent And Selective Nonsteroidal Indazolyl Amide Glucocorticoid Receptor Agonists
摘要:Modification Of A Phenolic Lead Structure Based On Lessons Learned From Increasing The Potency Of Steroidal Glucocorticoid Agonists Lead To The Discovery Of Exceptionally Potent,Nonsteroidal,Indazole Gr Agonists. Sar Was Developed To Achieve Good Selectivity Against Other Nuclear Hormone Receptors With The Ultimate Goal Of Achieving A Dissociated Gr Agonist As Measured By Human In Vitro Assays. The Specific Interactions By Which This Class Of Compounds Inhibits Gr Was Elucidated By Solving An X-Ray Co-Crystal Structure. (C) 2013 Published By Elsevier Ltd.
Doi:10.1016/j.Bmcl.2013.06.089

专利信息

专利号:US-11970456-B1
优先权日:2023-09-21
标题:Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning
发明人：BARI AHMED MUHAMMAD; GHANI USMAN
权利人:UNIV KING SAUD
摘要:A 2-((1H-indazol-5-yl)methylene)hydrazinecarbothioamide compound, its synthesis, and its use as a tyrosine kinase inhibitor. In particular, the synthesis of the 2-((1H-indazol-5-yl)methylene)hydrazinecarbothioamide compound as shown below. This compound has a high efficacy of inhibiting mushroom tyrosinase enzyme, and is a potent inhibitor of tyrosinase that can be used as an inhibitor of skin hyperpigmentation as well as an inhibitor of fruit and vegetable browning.

专利号:WO-2023072966-A1
优先权日:2021-10-26
标题:Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
发明人：DEAU EMMANUEL; GEORGE PASCAL; MEIJER LAURENT; MIEGE FRÉDÉRIC
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I) wherein R 1 represents a (C 4 -C 6) alkyl group, a (C 3 -C 8) cycloalkyl group, a bridged (C 6 -C 10 )cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C 1 -C 3 )alkanediyl group, and R' represents, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R''-L- group wherein L is a (C 1 -C 3 )alkanediyl group, and R'' is an optionally substituted phenyl group; R 2 is selected from the group consisting of a hydrogen atom and a (C 1 -C 3 )alkyl group; R 5 represents a hydrogen atom, a (C 1 -C 4 )alkyl group or a (C 3 -C 6 )cycloalkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits and neuroinflammation associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; osteoarthritis and tendinopathy; Duchenne muscular dystrophy; cancers and leukemias; neuroinflammation, anemia, infections caused by unicellular parasites, viral infections and for regulating body temperature.